1
|
Mremi A, Mwakyembe T, Wampembe E, Serventi F, Lodhia J. Primary breast squamous cell carcinoma: A case report at a tertiary hospital in Northern Tanzania. Clin Case Rep 2023; 11:e7586. [PMID: 37346880 PMCID: PMC10279938 DOI: 10.1002/ccr3.7586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 05/24/2023] [Accepted: 06/03/2023] [Indexed: 06/23/2023] Open
Abstract
Key Clinical Message Primary SCC of the breast is a very rare disease.Metastasis from elsewhere should be excluded first.The tumor is a very aggressive with poor prognosis.No standard treatment approaches are available.Managed by surgical excision followed by chemotherapy and radiotherapy. Abstract Primary squamous cell carcinoma of the breast is an exceedingly rare disease, and its management is still unclear. A-65-year-old lady presented with a progressive swelling of her right breast that started spontaneously. Other potential primary sites were ruled out. She was kept on a neo-adjuvant chemotherapy (AC-T protocol) of doxorubicin, adriamycin, and paclitaxel. Later, she was underwent modified radical mastectomy with axillary lymph node dissection. Her post-operative recovery was uneventful. Currently, she is followed up at oncology outpatient clinic.
Collapse
Affiliation(s)
- Alex Mremi
- Department of PathologyKilimanjaro Christian Medical CentreMoshiTanzania
- Faculty of MedicineKilimanjaro Christian Medical University CollegeMoshiTanzania
| | - Theresia Mwakyembe
- Faculty of MedicineKilimanjaro Christian Medical University CollegeMoshiTanzania
- Department of General SurgeryKilimanjaro Christian Medical CentreMoshiTanzania
| | - Elizabeth Wampembe
- Faculty of MedicineKilimanjaro Christian Medical University CollegeMoshiTanzania
- Department of General SurgeryKilimanjaro Christian Medical CentreMoshiTanzania
| | - Furaha Serventi
- Faculty of MedicineKilimanjaro Christian Medical University CollegeMoshiTanzania
- Cancer Care Center, Kilimanjaro Christian Medical CentreMoshiTanzania
| | - Jay Lodhia
- Faculty of MedicineKilimanjaro Christian Medical University CollegeMoshiTanzania
- Department of General SurgeryKilimanjaro Christian Medical CentreMoshiTanzania
| |
Collapse
|
2
|
Gao F, Li J, Liao H, Fan P, Wang M, Liu Y, Ding L, Du G. Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report. Front Pharmacol 2023; 14:1115422. [PMID: 37251309 PMCID: PMC10213914 DOI: 10.3389/fphar.2023.1115422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Accepted: 05/02/2023] [Indexed: 05/31/2023] Open
Abstract
Primary squamous cell carcinoma of the breast is a rare subtype of carcinoma of chemosis for which there is no effective chemotherapy regimen. Breast squamous cell carcinoma is usually "triple negative", with poor chemotherapy effects and poor prognosis. Here, we report a successful case of primary breast squamous cell carcinoma treated with apatinib. The patient was treated with 2 cycles of apatinib. The efficacy was evaluated as partial remission, and a sublesion of approximately 4 cm fell off.
Collapse
Affiliation(s)
- Fangfang Gao
- Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Jingtai Li
- Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Haoran Liao
- Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Pingming Fan
- Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- Guangxi Medical University Cancer Hospital, Nanning, China
| | - Minjian Wang
- Department of Pathology, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Yu Liu
- Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
| | - Linwei Ding
- Key Laboratory of Molecular Biology, Hainan Medical University, Haikou, China
| | - Guankui Du
- Department of Breast Surgery, The First Affiliated Hospital of Hainan Medical University, Haikou, China
- Key Laboratory of Molecular Biology, Hainan Medical University, Haikou, China
- Department of Biochemistry and Molecular Biology, Hainan Medical University, Haikou, China
- Biotechnology and Biochemistry Laboratory, Hainan Medical University, Haikou, China
| |
Collapse
|
3
|
Primary Squamous Cell Carcinoma of the Breast: A Case Report. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY 2022. [DOI: 10.1007/s40944-022-00631-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Lumpectomy Combined with Adjuvant Radiotherapy Could Be a Treatment Option for Primary Squamous Cell Carcinoma of the Breast. JOURNAL OF ONCOLOGY 2021; 2021:2497227. [PMID: 34899904 PMCID: PMC8660218 DOI: 10.1155/2021/2497227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 10/27/2021] [Accepted: 11/12/2021] [Indexed: 11/18/2022]
Abstract
Background To investigate the outcomes of primary squamous cell carcinoma (PSCC) of the breast undergoing radical surgery with or without adjuvant radiotherapy (RT). Materials and Methods A population cohort with histologically diagnosed PSCC of the breast was identified from the SEER database. The Kaplan-Meier method and Cox-regression proportional hazards model was used to assess the impact of surgical types with or without adjuvant RT on the cause-specific survival (CSS) and overall survival (OS). A retrospective analysis of PSCC between Jan 2010 and Dec 2018 from our institute was performed. Results A total of 515 patients with PSCC of the breast were included, 254 patients treated with mastectomy (MAST) alone, 78 with MAST + RT, 87 with lumpectomy (LUMP) alone, and 96 with LUMP + RT. The median follow-up time was 118 months (range: 0-379 months). In the multivariate Cox analyses, LUMP + adjuvant RT was an independent prognostic factor for CSS (p = 0.028) and OS (p = 0.048). Patients treated with LUMP + RT had better survival rates than patients who underwent lumpectomy (CSS, p = 0.034; OS, p = 0.0004), MAST alone (CSS, p = 0.0001; OS, p < 0.0001), and MAST + RT (CSS, p = 0.0001; OS, p = 0.0078), while postmastectomy RT did not significantly improve OS (p = 0.062) and CSS (p = 0.67) when compared to MAST alone. In addition, a total of 28 patients with PSCC of the breast were identified from our institute. All of these patients presented with estrogen receptor-negative type, and three of them had HER-2-positive PSCC; the median tumor size was 3 cm (range: 0.5-15 cm). Eight patients were treated with LUMP + adjuvant RT, thirteen with MAST, and seven with MAST + RT. Until the last follow-up of Sep 2021, 26 patients with PSCC were still alive and free of breast cancer, excepting that one patient treated with MAST and one patient with MAST + RT died from breast cancer. Conclusion PSCC of the breast after radical surgery has a poor prognosis. Adjuvant RT after LUMP significantly improves survival of patients with PSCC of the breast. Further studies are still needed to investigate the role of adjuvant RT in PSCC of the breast after mastectomy.
Collapse
|
5
|
Qi J, Hu Z, Xiao H, Liu R, Guo W, Yang Z, Ma K, Su S, Tang P, Zhou X, Zhou J, Wang K. SOX10 - A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma. Cancer Manag Res 2020; 12:4039-4044. [PMID: 32547236 PMCID: PMC7266319 DOI: 10.2147/cmar.s250867] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Introduction Differential diagnosis of metaplastic squamous cell carcinoma of breast (MSCCB) is difficult. In particular, in terms of metastatic MSCCB, because of the low speciality of traditional markers such as mammaglobin, gross cystic disease fluid protein-15 (GCDFP-15) and GATA binding protein 3 (GATA3), the most common problem is differentiating the spread of MSCCB to the lung from a primary lung squamous cell carcinoma. It is urgently required to explore a novel marker to aid in differential diagnosis. Aim The aim of this study is to explore a novel marker to aid in the differential diagnosis of MSCCB from other squamous cell carcinomas (SCC) in other organs. Methods We tested the expression of SOX10 in 375 human SCC specimens with immunohistochemistry (IHC). Results In a series of 20 MSCCB, 9 (45%) were positive for SOX10. All of them were triple-negative MSCCB. Conversely, SOX10 was totally negative in another 205 SCC originating from lung, skin, cervix, oral mucosa, and esophagus. In a series of 150 triple-negative breast cancer and their metastatic foci, SOX10 labeling in the primary tumor and metastasis was 78% and 79.3%, respectively, and the agreement rate was 97.3% (P>0.05). Conclusion Our findings demonstrate that SOX10 was recommended for differentiating MSCCB from non-mammary metastasis to the breast, as well as for distinguishing primary SCC from metastatic MSCCB, and SOX10 may be valuable in the pathological diagnosis of breast-derived metaplastic squamous cell carcinoma.
Collapse
Affiliation(s)
- Jialin Qi
- Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.,Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China
| | - Zhenmin Hu
- Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.,Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China
| | - Heng Xiao
- Department of Pathology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People's Republic of China
| | - Ruijie Liu
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China
| | - Wei Guo
- Department of Pathology, Hunan Provincial People's Hospital, Changsha, Hunan 410005, People's Republic of China
| | - Zhichun Yang
- Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, People's Republic of China
| | - Kewen Ma
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China
| | - Shitong Su
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China
| | - Ping Tang
- Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China
| | - Xunjian Zhou
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China
| | - Jianhua Zhou
- Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.,Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China
| | - Kuansong Wang
- Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.,Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China
| |
Collapse
|
6
|
Pirot F, Chaltiel D, Ben Lakhdar A, Mathieu MC, Rimareix F, Conversano A. Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? A series of 39 patients. Breast Cancer Res Treat 2020; 180:87-95. [PMID: 31970558 DOI: 10.1007/s10549-020-05525-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 01/09/2020] [Indexed: 11/24/2022]
Abstract
PURPOSE Squamous cell carcinoma (SCC) of the breast is a rare entity of breast cancer, with a very poor prognosis, and whose pathophysiology is still unwell established. Therapeutic management is very heterogeneous due to its incomplete understanding. Nevertheless, it seems that two histological entities can be distinguished: pure SCC close to the cutaneous origin, and metaplastic squamous breast cancer (MSBC). The aim of this study is therefore to assess the difference in survival according to the histological type (SCC or MSBC) and to describe the demographic, clinical, and therapeutic characteristics of the two underlying populations. METHODS Our data came from a monocentric retrospective series of 39 patients treated between 1985 and 2018 at the Gustave Roussy Institute (France) for a breast SCC. RESULTS Of the 39 patients included, 64% had MSBC and 36% had a pure form. The overall and recurrence-free survival at 3 years [CI 95%] was 72.3% [56.9%; 87.0%] and 67.2% [51.2%; 83.2%], respectively. The overall 3-year survival of patients with MSBC was significantly lower than that with pure SCC: HR [CI 95%] 9.5 [1.2; 73.1], p = 0.008. The 3-year recurrence-free survival of patients with MSBC was also poorer: HR [CI 95%] 11.9 [1.6; 90.7], p = 0.002. Patients with MSBC also tended to be younger, have a large lesion size, and be more metastatic. CONCLUSION The histological nature of SCC seems to bring fundamental new elements to the therapeutic management as it impacts recurrence and survival. It should therefore be better characterized at diagnosis in order to possibly adapt treatments.
Collapse
Affiliation(s)
- F Pirot
- Department of Plastic and Reconstructive Surgery, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.
| | - D Chaltiel
- INSERM U1018, CESP, Fac. de Médecine-Univ. Paris-Sud-UVSQ, INSERM, Université Paris-Saclay, 94807, Villejuif Cedex, France
- Gustave Roussy, Service de Biostatistique et d'Epidémiologie, 94805, Villejuif, France
| | - A Ben Lakhdar
- Department of Pathology, Gustave Roussy, University Paris-Saclay Villejuif, Villejuif, France
| | - M C Mathieu
- Department of Pathology, Gustave Roussy, University Paris-Saclay Villejuif, Villejuif, France
| | - F Rimareix
- Department of Plastic and Reconstructive Surgery, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - A Conversano
- Department of Plastic and Reconstructive Surgery, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| |
Collapse
|
7
|
Harb OA, Baiomy TA, Abdelhamid MI, Gertallah LM, Obaya AA, Basha MAA. Combination of both primary pure squamous cell carcinoma (SCC) and conventional invasive lobular carcinoma (ILC) in the same breast; A rare case report and review of the literature. HUMAN PATHOLOGY: CASE REPORTS 2019. [DOI: 10.1016/j.ehpc.2019.200333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
8
|
Darlington CD, Anitha GFS. Squamous Cell Carcinoma of the Breast Mimicking Chronic Breast Abscess. Niger J Surg 2019; 25:101-103. [PMID: 31007522 PMCID: PMC6452756 DOI: 10.4103/njs.njs_22_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Primary squamous cell carcinoma (SCC) of the breast is an exceedingly rare malignancy, and there are no clear management protocols for SCC of the breast. We report a 45-year-old female patient who presented with the recurrent breast abscess and a large fungating SCC of the breast with fixed ipsilateral axillary nodes. She was offered modified radical mastectomy. During the follow-up visits, she was observed to have developed multiple vertebral metastases. She had palliative chemotherapy. However, the patient succumbed to the disease within 6 months of the diagnosis.
Collapse
Affiliation(s)
- C Danny Darlington
- Department of Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
| | - G Fatima Shirly Anitha
- Department of Pediatrics, CSI Kalyani Multispeciality Hospital, Mylapore, Chennai, Tamil Nadu, India
| |
Collapse
|